AbbVie Inc. (ABBV) on Friday raised the lower end of its full-year adjusted profit guidance as it reported better-than-expected adjusted profit and sales.
The biopharmaceutical company narrowed its adjusted per-share earnings guidance to between $8.90 and $8.92 from between $8.82 to $8.92. The guidance excludes $3.82 a share of intangible asset amortization expense and non-cash charges, the company said.
AbbVie lowered its per-share earnings guidance to between $5.08 and $5.10 from between $5.69 and $5.79. The metric includes a non-cash charge related to the launch of the psoriasis treatment Skyrizi.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.